Drugs / PA3670
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05851261 | Apr → Oct 2023 | chronic hepatitis B virus infection | Zhejiang Palo Alto Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PA3670 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05851261 ↗ |
| Route | Oral | “single and multiple oral administration” NCT05851261 ↗ |